Asia PR News

TIRAT CARMET, Nov. 29 /PRNewswire-AsiaNet/ -

InSightec Ltd. today reported that it has closed an internal round of
financing totaling $30 million from its existing investors: Elbit Imaging Ltd.
(Nasdaq: EMITF), GE Capital Equity Holdings Inc., a subsidiary of General
Electric Company (NYSE: GE), MediTech Advisors LLC ("MTA"), a private firm
specializing in the healthcare marketplace, and directors and managers of the
company.

The investment will take the form of Preferred Shares, which are
convertible to InSightec’s ordinary shares subject to the fulfillment of
certain conditions stipulated in the agreement.

InSightec reported that the funds would be used to expand its research and
development efforts, for marketing and sales activities, and for general
corporate purposes.

InSightec’s President and CEO Dr. Kobi Vortman said, "The ExAblate(R) 2000
treatments of uterine fibroids continue to grow globally with excellent
clinical results driving market adoption and with more than 50 leading sites
globally. In parallel InSightec is expanding the research into oncology areas:
bone metastases, prostate cancer, breast cancer, liver tumors and brain
tumors. InSightec has received the European CE approval for pain palliation of
bone metastases based on clinical results demonstrating that this technology
has the potential to become an important treatment alternative for this
patient population and also received from the FDA IDE approval for starting a
phase III clinical trial in the US for the treatment of bone metastases. The
investment will allow acceleration of the technical and clinical research for
oncology applications providing improved care for patients around the world.

The continued support by our current investors is a vote of confidence in
the employees, the technology and the vision, and we are proud in it."

About InSightec
InSightec Ltd. is a privately held company owned by Elbit Imaging, General
Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to
develop the breakthrough MR guided Focused Ultrasound technology and transform
it into the next generation operating room. Headquartered near Haifa, Israel,
the company has over 150 employees and has invested more than $100 million in
research, development, and clinical investigations. Its U.S. headquarters are
located in Dallas, Texas. For more information, please go to:
http://www.insightec.com/

About ExAblate
The ExAblate(R) is the first system to use the breakthrough MRgFUS
technology that combines MRI — to visualize tissues in the body, plan the
treatment and monitor treatment outcome in real time — and high intensity
focused ultrasound to thermally ablate tumors inside the body non-invasively.
MR thermometry, provided uniquely by the system, allows the physician to
control and adjust the treatment in real time to ensure that the targeted
tumor is fully treated and surrounding tissue is spared. ExAblate received FDA
approval for the treatment of symptomatic uterine fibroids in October 2004.
ExAblate has been recognized for its innovation and potential to serve mankind
and has been awarded the 2004 European Union’s Information Society
Technologies grand prize, The Wall Street Journal’s 2004 Technology Innovation
Awards, Advanced Imaging’s 2005 Solutions of the Year, the Red Herring 100
Europe 2007 Award.

Contact Information:
InSightec Ltd.
http://www.insightec.com/
Tel: +972-4-813-1313
Email: info@insightec.com

For media inquiries:
Fern Lazar
Lazar Partners, Ltd.
Tel: (212) 867-1762
Email: flazar@lazarpartners.com

SOURCE InSightec Ltd.

CONTACT: InSightec Ltd., +972-4-813-1313, info@insightec.com; or Fern
Lazar of Lazar Partners, Ltd., +1-212-867-1762, flazar@lazarpartners.com
Web site: http://www.insightec.com